A due diligence call rarely opens with a question about your device. It opens with a request: let's look at your behind-the-scenes documentation. Founders walk into that moment ready to defend their technology, only to find an investor searching for something else entirely... whether the team can execute under regulatory scrutiny without falling apart.
That difference between what founders prepare for and what investors actually probe is where a lot of pre-market medtech companies lose ground they.
Venture capitalists evaluating medtech deals are not regulatory experts, and most won't pretend to be. But they've sat through enough diligence cycles to recognize a pattern: teams with a real quality system tend to hit their milestones, and teams without one tend to discover expensive problems right when they can least afford them. On the Inside the Investor's Mind podcast, investor Josh Eckelberry of Solas BioVentures described this evaluation as a de-risking exercise, one where team dynamics and execution discipline carry as much weight as the clinical case for the device itself. A scattered folder of shared drive documents and half-finished SOPs tells an investor something specific, and it isn't flattering.
The stakes show up later in the process too (not just at the term sheet). Thirty-five percent of initial 510(k) submissions get rejected for formatting and structural issues alone, not clinical or scientific ones. That statistic has less to do with whether the device works, and more to do with whether the paperwork behind it was built to survive contact with a regulator. Investors who have watched a portfolio company eat a six-month resubmission delay don't forget it, and they start asking about quality systems earlier in subsequent deal.
Founders sometimes assume the fix is proportional: a startup with three employees shouldn't need the same documentation rigor as a company shipping its fifth product. That instinct true to an extent... But it can also send the wrong signal.
An investor doesn't read a missing design history file as "they're early stage, that's fine." They read it as a preview of how the team handles complexity it hasn't faced yet. If document control is already inconsistent at five employees, what happens at fifty, under an FDA inspection, with a submission deadline three weeks out? That's the question the diligence request is looking to answer.
Contrast that with a startup that walks into a raise with traceable design inputs, a working CAPA process, and a document control system that doesn't require an email chain to locate the current SOP version. The technology pitch hasn't changed, but the credibility underneath it has.
Most pre-market medtech companies don't have a QA hire at all when they start building their quality foundation, and they shouldn't need one just to look serious to investors. What separates them from the best in class, however, is a system that captures traceability and document control on its own, rather than a manual scramble to rebuild a design history file the week before diligence starts.
That's a large part of why the MedTech Startup Survival Guide with Steve Bell kept coming back to validation and structure as much as it did product-market fit. Startups that survive their first few years tend to be the ones that build repeatable processes early, even lightweight ones, rather than the ones betting everything on speed alone.
Greenlight Guru was built for that exact tension. It gives founders IEC 62304, ISO 14971, and QMSR-aligned defaults out of the box, so a lean team can stand up a working quality system in five to eight weeks instead of the six-to-nine-month timeline a generic or enterprise platform typically demands. Every design change, risk assessment, and document revision gets logged automatically, tied to the tools engineers already use. Companies running on that kind of system see a 3.5 times reduction in the likelihood of major audit findings, without hiring a dedicated quality specialist just to keep the paperwork current. That's the audit trail investors like to see, whether or not anyone remembered to update a spreadsheet that week.
None of this replaces a strong clinical case or a defensible market thesis. Investors still fund technology and teams first. But readiness has become part of the pitch itself, and an important part of the compliance story found in the data room. Pre-market fundraising is crowded, and a full list of active medical device VC firms makes that obvious at a glance. Crowded rounds reward founders who remove friction wherever they can find it, and a clean quality system removes one of the largest friction points in diligence: the moment an investor has to ask, twice, where a document actually lives.
The founders who treat their QMS as a credibility asset rather than a delayed task tend to walk into fundraising conversations with one less thing to defend. That's worth more than the paperwork suggests.
Everything above is written for the founder sitting across the table from you. But the same story works both directions, and it's worth considering what a portfolio company's quality system does for you specifically, not just for them.
Diligence on a single company is manageable. Diligence repeated across ten or twenty portfolio companies, each running a different homemade version of document control, is not. When portfolio companies standardize on the same quality foundation, your team stops relearning a new filing system every time you check in on a company's regulatory progress. Design history, risk files, and CAPA status look the same across the portfolio, which makes your own diligence faster the second time and every time after.
The audit-risk math compounds across a portfolio the same way it compounds within a single company. A 3.5 times reduction in the likelihood of major audit findings is a meaningful number for one company's valuation. Multiply that across every device company you back, and it becomes a meaningful reduction in the number of portfolio-wide fire drills your team has to manage in a given year.
Time matters just as much. Every week a portfolio company spends building a quality system from scratch is a week not spent on the milestones that trigger the next round. Five to eight weeks to an audit-ready system, instead of six to nine months, means the capital you already deployed goes further before you have to decide whether to extend the runway or write the next check. That is the kind of operational advantage that shows up in your own fund's numbers, not just your portfolio company's.
None of this requires you to dictate tooling to a founder you're backing. But it's useful to know what a right-sized quality system buys everyone at the table.
If you're building your fundraising and quality readiness case at the same time, these related guides go deeper on the specific components:
Ready to see what a five-to-eight-week path to a diligence-ready QMS actually looks like, whether you're the founder building it or the investor asking about it? Get a demo of Greenlight Guru and find out what your quality system could be signaling right now.